What is Orgovyx, and what patent issues are linked to it?
Orgovyx is the brand name for relugolix (an oral androgen receptor pathway inhibitor used in prostate cancer treatment). Patent coverage and disputes around relugolix matter because they can affect when cheaper generics or competing products can enter.
DrugPatentWatch.com is a useful starting point for tracking relugolix/Orgovyx patent filings, status, and related legal developments. [1]
When does the Orgovyx patent (or exclusivity) expire?
Expiration depends on the specific patent(s) and the type of protection (for example, method, composition-of-matter, or formulation patents, plus any regulatory exclusivity). To get the most accurate expiry timing, you typically need to look at each listed patent in the DrugPatentWatch database and its expected expiration / status. [1]
Who makes Orgovyx, and what does that mean for patent ownership?
Ownership matters because patents are usually listed under the brand-holder or related assignees. Checking the assignees and listed patents on DrugPatentWatch helps you identify:
- who holds the relevant patents, and
- which patents are likely to block competitors. [1]
Are there challenges or lawsuits related to Orgovyx patents?
Patent litigation can shift the timeline for generic entry even before the nominal patent expiry date. DrugPatentWatch tracks patent-linked developments and can point you to relevant filings and parties. [1]
How can you check the exact Orgovyx patent you care about?
If you’re searching by a specific goal—like “earliest generic entry” or “which patent is blocking”—you’ll want to review the individual patent records (not just the product name) and note:
- patent numbers,
- scope (what it protects),
- projected expiration dates,
- current status (active/expired/litigated). [1]
Source
- DrugPatentWatch – Orgovyx (relugolix) patents and exclusivity